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Sex Differences in the Association Between Frailty and
Sarcopenia in Patients With Cirrhosis
Laila Fozouni, MPH1, Connie W. Wang, MD2 and Jennifer C. Lai, MD, MBA2
OBJECTIVES: Frailty is prevalent in patients with cirrhosis and is hypothesized to result in part from sarcopenia, but
the precise contribution of sarcopenia to frailty in this population is poorly understood.
METHODS: Includedwere patients with cirrhosis from2011 to 2014who had an ambulatory frailty assessment and
abdominal computed tomography scan within 3 months. Logistic regression assessed the associations
between frailty (5Liver Frailty Index ‡4.5), and sarcopenia (5skeletal muscle index of <39 cm2/m2 for
women and <50 cm2/m2 for men).
RESULTS: Two hundred ninety-one participants were included: 33% were female. The median (interquartile range)
Liver Frailty Index was 3.7 (3.3–4.2); 19% were frail. The median (interquartile range) skeletal muscle
indexwas49cm2/m2 (31–69); 36%had sarcopenia. Among the54 frail participants, 48%had sarcopenia.
In univariable logistic regression, sarcopenia was associated with a 1.863 increased odds of being frail
(95% confidence interval [CI], 1.02–3.38). After adjusting for sex, etiology, hepatocellular carcinoma,
MELDNa, ascites, encephalopathy, and hypertension, sarcopenia was associated with a 2.383 increased
odds of being frail (95% CI, 1.17–4.85). After stratifying by sex and adjusting for MELDNa, sarcopenia
among males was associated with a significantly increased odds of frailty (odds ratio 2.81, 95% CI,
1.19–6.67), whereas sarcopenia among females was not (odds ratio 1.38; 95% CI, 0.45–4.25).
DISCUSSION: In patients with cirrhosis, sarcopenia was associated with a nearly 2-fold increased odds of being frail.
Two-thirds of frail men displayed sarcopenia compared with only one-quarter of frail women.
Contributors to the frail phenotype may differ by sex and support the need for sex-specific strategies to
reduce frailty in this population.
Clinical and Translational Gastroenterology 2019;10:e00102. https://doi.org/10.14309/ctg.0000000000000102
INTRODUCTION
Cirrhosis is characterized by chronic systemic inflammation and
undernutrition. These 2 factors have been described as potent
and mutual drivers of muscle loss, known as sarcopenia, as well
as loss of physiologic reserve, known as frailty (1, 2). Both sar-
copenia and frailty are prevalent in patients with cirrhosis and
have been shown to be critical determinants of mortality in this
population (3, 4). Studies have also shown a differing prevalence,
as well as differing impact on outcomes, of frailty and sarcopenia
by etiology of cirrhosis (5). Little is known of the overlap between
the two.
Conceptually, frailty has been defined as a biologic syndrome of
decreased physiologic reserve that results from the derangement of
multiple physiologic systems (e.g., inflammatory, endocrine, and
cardiac) (6, 7). The cumulative effects of this long-standing de-
rangement lead to a reduction in physical activity, chronic un-
dernutrition, and muscle loss. For patients with cirrhosis, in whom
hepatic synthetic dysfunction may accelerate muscle loss, sarcopenia
may be the dominant driver of the frailty phenotype.
Recently, we developed the Liver Frailty Index, an objective,
performance-based metric derived and validated in patients with
cirrhosis, that is reliable, reproducible, and has strong validity for
the construct of frailty (4, 8, 9).With this conceptual framework,we
aimed to evaluate the relationshipbetween frailty and sarcopenia in
patients with cirrhosis. We hypothesized that sarcopenia would be
prevalent among those who displayed the frail phenotype.
METHODS
Patients and baseline data collection
We analyzed data from the Functional Assessment in Liver
Transplantation (FrAILT) Study, a prospective cohort study of
adult patients with cirrhosis who were actively listed for liver
transplant at a single center and seen in the ambulatory setting for
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a clinic visit. Patients enrolled from November 1, 2011, through
November 30, 2014, were eligible for inclusion in this study.
For inclusion in the study, all candidates must have undergone
an abdominal computed tomography (CT) scan within 3 months
of frailty testing. Indications for undergoing CT scans among the
includedpatientswere hepatocellular carcinoma (HCC)evaluation
or follow-up (51%), HCC screening (22%), preliver transplant
evaluation (5%), evaluation for portal vein thrombosis (4%), and
the remaining for acute indications including abdominal pain and
sepsis (17%). Five patients were excluded because their CT scans
did not adequately capture abdominal wall musculature.
At initial visit, data regarding demographics and medical
comorbidities (e.g., hypertension and diabetes) were collected
from the patient’s electronic health record. Hepatic encepha-
lopathy was categorized as none/mild, moderate, or severe based
on a Numbers Connection Test time of #60 seconds, 60–120
seconds, or .120 seconds, respectively.
Muscle mass and quality assessment
On axial CT images, skeletal muscles were identified at the third
lumbar (L3) vertebral level and quantified within standard
Hounsfield units thresholds of 229 to 1150. Sarcopenia was
defined as a skeletal muscle index (SMI) of,50 cm2/m2 for men
and ,39 cm2/m2 for women (3).
All CT images were analyzed by a single trained researcher
using a CT scan postprocessing workstation (Advantage Win-
dows 2.2, Volume Viewer software, GE Healthcare, Waukesha,
WI). We have previously reported that interobserver correlation
was 98% for muscle mass measurements using this technique (3).
Frailty assessment
Frailty was assessed at an outpatient clinic visit using the Liver
Frailty Index, which consists of 3 performance-based tests (4):
1. Grip strength: the average of 3 trials, measured in the patient’s
dominant hand using a hand dynamometer;
2. Timedchair stands:measuredas thenumberof seconds it takes to
do 5 chair stands with the patient’s arms folded across the chest;
3. Balance testing: measured as the number of seconds that the
patient can balance in 3 positions (feet placed side to side,
semitandem, and tandem) for a maximum of 10 seconds each.
With these 3 individual tests of frailty, the Liver Frailty Index
was calculated using the following equation (calculator available
at: http://liverfrailtyindex.ucsf.edu):
ð2 0:3303 gender-adjusted grip strengthÞ
1 ð2 2:5293 number of chair stands per secondÞ
1 ð2 0:0403 balance timeÞ1 6:
Patientswere categorized as frail based on previously established
cutoffs if they had a Liver Frailty Index score of$4.5 at the time of
their last assessment before liver transplant (4).Wehave established
the reliability and reproducibility of these cut-points (8).
Statistical analysis
Baseline demographics were presented as medians (interquartile
ranges [IQR]) for continuous variables or percentages for cate-
gorical variables and compared by frailty status using Wilcoxon
rank-sum or x2 tests. Logistic regression was used to assess asso-
ciations between frailty and sarcopenia. All variables associated
with the outcome of interest with a P value of,0.2 in univariable
analysis or that differed significantly by sex (etiology, HCC, hy-
pertension, andMELDNa) were evaluated for inclusion in the final
model. Backward stepwise regressionwas then performed toderive
the final multivariable model, which included only variables as-
sociated with a P value of,0.05.
Statistical analyses were performed using Stata (v15, SE). The
institutional review board at the participating site approved this
study.
RESULTS
Characteristics of the entire patient population
A total of 291 patients with cirrhosis were included. Baseline
characteristics of the cohort are shown in Table 1. To summarize
key baseline characteristics, median (IQR) age was 60 years
(54–64), 33% were female, 55% were non-Hispanic white, and
median body mass index (BMI) was 27 kg/m2. The primary eti-
ology of cirrhosis was chronic hepatitis C in 60%, alcoholic liver
disease in 11%, and nonalcoholic steatohepatitis in 8%. Rates of
hypertension were 44% and those of diabetes were 34%. The
median (IQR) MELDNa score was 17 (13–22) and albumin was
3.0 g/dL (2.6–3.4). The proportion with Child-Pugh A, B, and C
was 28%, 51%, and 22%, respectively.
Comparison of baseline characteristics by frailty and sarcopenia
The median (IQR) Liver Frailty Index was 3.7 (3.3–4.2). Fifty-four
(19%) patients were classified as frail. Compared with nonfrail
patients, frail patients were more likely to be female (44% vs 31%)
and Hispanic white (31% vs 24%). Frail patients were less likely to
have chronic hepatitis C (50% vs 62%) and HCC (30% vs 50%).
Frail patients had higher median MELDNa (22 vs 16), higher
median total bilirubin (3 vs 2.2mg/dL), and lowermedian albumin
(2.7 vs 3 g/dL). Frail patients hadhigher incidenceof ascites (61%vs
25%), hepatic encephalopathy (33% vs 15%), and waitlist death
(37% vs 17%). However, frail and nonfrail patients had similar
median age, BMI, and incidence of hypertension and diabetes.
The median SMI in this cohort was 49 (31–69) cm2/m2. One
hundred five (36%) patients met the criteria for having sarcope-
nia. Compared with patients without sarcopenia, patients with
sarcopenia were less likely to be female (19% vs 42%) or Hispanic
white (20% vs 29%) and had a lower median BMI (26 vs 28 kg/
m2). However, patients with and without sarcopenia had similar
etiologies of liver disease, similar rates of HCC, and similar
MELDNa and median albumin.
Relationship between frailty and sarcopenia
Atotal of 54patientsmet the criteria for frail, and105patientsmet the
criteria for sarcopenia; 26 met the criteria for both frail and sarco-
penia.Among the54patientswhowere frail, 48%alsohadsarcopenia.
Among the 105 patients who had sarcopenia, 25% were also frail.
In univariable logistic regression, sarcopenia was associated
with a 1.86 times increased odds of being frail (95%CI, 1.02–3.38,
P 5 0.04). In multivariable regression, after adjusting for sex,
etiology, HCC, MELDNa, ascites, encephalopathy, and hyper-
tension, sarcopenia was associated with a 2.38 times increased
odds of being frail (95% CI, 1.17–4.85; P 5 0.02) (Table 2).
We observed significant differences in the relationship be-
tween frailty and sarcopenia by sex (Figure 1). Among the 193
men, a total of 20 (10%) men met the criteria for both frail and
sarcopenia. Among the 30 (16%) men who met the criterion for
frail, 67% also met the criterion for sarcopenia. Among the 85
(44%) men who met the criterion for sarcopenia, 24% also met





Table 1. Baseline characteristics of the 291 patients with cirrhosis, categorized by frailty and by sarcopenia
All
Comparison by frailty Comparison by sarcopenia
Not frail (n5 163) Frail (n5 30) P value No sarcopenia (n5 74) Sarcopenia (n5 24) P value
Female 34% 31% 44% 0.06 42% 19% ,0.001
Age, yr 60 (54–64) 61 (55–64) 59 (50–65) 0.34 60 (54–64) 61 (56–65) 0.26
Follow-up time, mo 15 (9–23) 15 (9–23) 17 (10–23) 0.47 15 (9–23) 15 (9–23) 0.70
Race/ethnicity
Non-Hispanic white 55% 55% 54% 0.35 53% 60% 0.10
Black 5% 6% 0% 6% 3%
Hispanic white 26% 24% 31% 29% 20%
Asian/Pacific Islander 8% 8% 7% 5% 11%
Other 6% 6% 7% 6% 6%
Body mass index, kg/m2 27 (24–31) 28 (24–31) 27 (23–32) 0.45 28 (25–33) 26 (24–29) ,0.001
Etiology of liver disease
Chronic hepatitis C 60% 62% 50% 0.10 60% 59% 0.93
Alcohol 11% 11% 11% 11% 10%
Nonalcoholic
steatohepatitis
8% 7% 13% 9% 7%
Hepatitis B virus 7% 7% 7% 6% 9%
Autoimmune/cholestatic 10% 11% 7% 10% 10%
Other 5% 3% 11% 4% 6%
HCC 46% 50% 30% 0.007 47% 45% 0.74
Medical comorbidities
Hypertension 44% 44% 43% 0.82 48% 37% 0.08
Diabetes 34% 32% 43% 0.16 35% 33% 0.78
Laboratory tests
MELDNa 17 (13–22) 16 (13–20) 22 (17–26) ,0.001 17 (14–21) 18 (13–23) 0.64
Total bilirubin, mg/dL 2.3 (1.5–3.8) 2.2 (1.5–3.5) 3 (1.8–6.8) 0.002 2.3 (1.6–3.6) 2.1 (1.5–4) 0.82
Creatinine, mg/dL 0.9 (0.7–1.2) 0.9 (0.7–1.1) 1.1 (0.8–1.5) ,0.001 0.9 (0.7–1.1) 1 (0.8–1.3) 0.01
International Normalized
Ratio
1.4 (1.2–1.6) 1.3 (1.2–1.5) 1.4 (1.3–1.7) 0.02 1.4 (1.2–1.6) 1.4 (1.2–1.5) 0.45
Sodium, mEq/L 136 (134–139) 137 (134–139) 135 (132–138) 0.01 137 (134–139) 135 (134–138) 0.12
Albumin, g/dL 3 (2.6–3.4) 3 (2.6–3.5) 2.7 (2.4–3.2) 0.004 2.9 (2.6–3.4) 3.1 (2.6–3.6) 0.15
Ascites 31% 25% 59% ,0.001 28% 37% 0.11
Encephalopathy 18% 15% 33% 0.001 20% 14% 0.19
Child-Pugh score
A 28% 32% 8% ,0.001 27% 29% 0.82
B 51% 50% 51% 52% 48%
C 22% 17% 42% 21% 23%
Waitlist outcome
Waiting 33% 38% 11% ,0.001 34% 31% 0.37
Died/delisted 21% 17% 37% 20% 23%
Transplanted 41% 39% 48% 39% 44%
Other 5% 5% 4% 7% 2%
HCC, hepatocellular carcinoma.
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the criterion for frail. A total of 6 (6%) women met the criteria
for both frail and sarcopenia. Among the 98 women, 24 (24%)
met the criterion for frail, of whom 25% had sarcopenia. Among
the 20 (20%) women who met the criterion for sarcopenia, 30%
also met the criterion for frail. After stratifying by sex and
adjusting forMELDNa, sarcopenia amongmales was associated
with a 2.81 times increased odds of frailty (95% CI 1.19–6.67, P
5 0.02), whereas sarcopenia among females was not signifi-
cantly associated with frailty (odds ratio 1.38; 95% CI 0.45–4.25,
P 5 0.55). A test of homogeneity demonstrated no evidence of
effect measure modification by sex on the relationship between
sarcopenia and frailty (P 5 0.28).




Odds ratio 95% CI P value Odds ratio 95% CI P value
Sarcopenia 1.86 1.02–3.38 0.04 2.38 1.17–4.85 0.02
Female 1.76 0.96–3.22 0.07 2.34 1.14–4.80 0.02
Etiologya, reference group
chronic hepatitis C
Alcohol 1.31 0.49–3.48 0.59 — — —
Nonalcoholic steatohepatitis 2.38 0.90–6.34 0.08 — — —
Hepatitis B virus 1.36 0.42–4.39 0.61 — — —
Autoimmune/cholestatic 0.87 0.28–2.70 0.81 — — —
Other 4.08 1.31–12.71 0.02 — — —
HCCa 0.42 0.22–0.80 0.008 — — —
Diabetes 1.54 0.84–2.82 0.16 — — —
MELDNa, per pointa 1.13 1.07–1.19 ,0.001 1.09 1.03–1.16 0.002
Ascites 4.39 2.37–8.14 ,0.001 3.00 1.64–5.51 ,0.001
Encephalopathy 2.89 1.48–5.64 0.002 2.35 1.34–4.11 0.003
Hypertensiona 0.93 0.51–1.69 0.819 — — —
Only variables associated with a P value ,0.2 in univariable analysis or that differed significantly by sex are presented in this table.
HCC, hepatocellular carcinoma.
aDiffered significantly by sex (P, 0.05).
Figure 1. Box and whisker plot of the median skeletal muscle index by frailty status and sex.






It is now well established that both frailty and sarcopenia are
prevalent in patients with cirrhosis, and studies have shown that
frailty is a more reliable predictor of adverse outcomes in this
population (10). Conceptually, sarcopenia has been described as
an integral component of the frail phenotype, as operationalized
by the classic Fried Frailty Phenotype for community-dwelling
older adults (6). By this framework, multiple systemic
derangements resulting from aging, undernutrition, and
chronic disease lead to sarcopenia, which then predispose an
older adult to the clinical manifestation of frailty. Whether this
conceptual pathway applies to patients with cirrhosis—who
experience undernutrition and muscle wasting predominantly
from the liver disease itself rather than chronologic aging—has
not been characterized.
In this study of 291 patientswith cirrhosis, we report high rates
of frailty (19%) and even higher rates of sarcopenia (36%). Sar-
copenia was associated with greater than 2 times an adjusted odds
of being frail, suggesting a strong relationship between sarcopenia
and frailty. However, only 48% of those whomet the criterion for
frail also met the criterion for sarcopenia. The low prevalence of
HCC and higher median MELDNa scores among frail patients,
neither of which differed by sarcopenia status, further supports
the importance of understanding the frailty phenotype among
patients with cirrhosis and reinforces the distinct nature of frailty
from sarcopenia. These findings add substantially to our current
understanding of frailty and sarcopenia in patients with cirrhosis
not only by quantifying the contribution of sarcopenia to the frail
phenotype but also by opening the door to new investigations to
uncovering other contributors to frailty in this chronic disease
state. Such factors that have been proposed in the field of geri-
atrics (where the construct of frailty originated) that may be
particularly relevant to patients with cirrhosis include—but are
not limited to—impaired cognition, psychological distress, sys-
temic inflammation, or hormonal imbalance (7).
Of particular interest was the sex difference that we observed
in the relationship between frailty and sarcopenia. Although
two-thirds of frail men with cirrhosis had sarcopenia, only one-
quarter of frail women had sarcopenia. The reason for this
finding is unknown, but it is not the first report of sex differences
with respect to sarcopenia in patients with cirrhosis. Previous
data have demonstrated higher rates of sarcopenia in men
comparedwithwomen, as well as a stronger association between
sarcopenia and waitlist mortality or posttransplant outcomes in
men compared with women (3, 11–17). These findings em-
phasize the importance of developing large cohorts of patients
with cirrhosis enriched with women and conducting sex-
subgrouped analyses when studying frailty and sarcopenia. Our
findings also support further investigation into the use of tes-
tosterone in men with cirrhosis and low testosterone, which has
been shown to increase leanmuscle mass, decrease fat mass, and
improve grip strength (18).
Our study used outpatient testing to identify patients who
were classified as frail and sarcopenic, but we acknowledge that
acute illness, such as acute on chronic liver failure, could sub-
stantially impact a patient’s frailty status and/or SMI during the
course of their illness. Future studies are necessary to un-
derstand the role of acute hospitalization on changes in both
frailty and sarcopenia.
We acknowledge the following limitations to our study.
Because this study was a cross-sectional study, we were not able
to evaluate the causal relationship between frailty and sarco-
penia. However, traditional frameworks of frailty firmly situate
sarcopenia in the causal pathway of frailty (6) (i.e., sarcopenia
contributes to the frail phenotype), so we elected to present the
data in this direction. Second, our cohort had relatively few frail
women, so we were unable to fully investigate hypotheses re-
lated to the sex differences in the frailty-sarcopenia relationship
that we described. Third, because of low numbers, we were
relatively underpowered for survival analysis. In addition, be-
cause abdominal CT scans are not obtained as part of standard
of care in all patients with cirrhosis, our cohort only included
those patients who had an abdominal CT scan performedwithin
3 months of frailty assessment, which may have led to bias to-
ward selecting patients who were, perhaps, sicker (and there-
fore, requiring an abdominal CT scan for evaluation). However,
the median Liver Frailty Index was similar to the median Liver
Frailty Index and MELDNa that we reported in our original
cohort, suggesting that the patients included in this specific
study were not substantially different from the larger population
of patients with cirrhosis awaiting liver transplantation. Last,
our cohort included only patients with cirrhosis who were seen
as outpatients and had a relatively low MELDNa score (and the
Liver Frailty Index has only been validated in an outpatient
population). Additional studies are necessary to confirm
whether our observations apply to higherMELDNa patients and
those cared for as inpatients.
Despite these limitations, our study is the first to quantify
the contribution of sarcopenia to the frail phenotype using the
newly developed Liver Frailty Index and provides further evi-
dence to support the fact that frailty and sarcopenia are not
synonymous. The sex differences that we observed in the re-
lationship between frailty and sarcopenia are novel—and
highlight the importance of sex-stratified analyses of frailty and
sarcopenia in the future. Understanding sex-specific factors
that lead to frailty are essential to develop therapeutic inter-
ventions targeting the lethal cirrhotic manifestation of frailty,
whether they be pharmacologic, activity-based, or environ-
mental. Our data lay the groundwork for this important
interventional work.
CONFLICTS OF INTEREST
Guarantor of the article: Jennifer C. Lai, MD, MBA, accepts full
responsibility for the conduct of the study.
Specific author contributions: L.F.: analysis and interpretation of
data and drafting of the manuscript. C.W.W.: acquisition of data and
critical revision of the manuscript. J.C.L.: study concept and design,
drafting of manuscript, and critical revision of the manuscript.
Financial support: This study was funded by NIH K23AG048337
(Lai), NIH R01AG059183 (Lai), the National Center for Advancing
Translational Sciences, National Institutes of Health, through
UCSF-CTSI Grant Number TL1 TR001871 (Fozouni). These
funding agencies played no role in the analysis of the data or the
preparation of this manuscript. Its contents are solely the re-
sponsibility of the authors and do not necessarily represent the
official views of the NIH.
Potential competing interests: None to report.




Sex Differences in Frailty and Sarcopenia 5
REFERENCES
1. Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia
Muscle 2012;3(4):225–37.
2. Lai JC, Feng S, Terrault NA, et al. Frailty predicts waitlistmortality in liver
transplant candidates. Am J Transplant 2014;14(8):1870–9.
3. Carey EJ, Lai JC, Wang CW, et al. A multicenter study to define
sarcopenia in patients with end-stage liver disease. Liver Transpl 2017;
23(5):625–33.
4. Lai JC, Covinsky KE, Dodge JL, et al. Development of a novel frailty index
to predict mortality in patients with end-stage liver disease. Hepatology
2017;66(2):564–74.
5. Bhanji RA, Narayanan P, Moynagh MR, et al. Differing impact of
sarcopenia and frailty in nonalcoholic steatohepatitis and alcoholic liver
disease. Liver Transpl 2019;25(1):14–24.
6. Fried LP, TangenCM,Walston J, et al. Frailty in older adults: Evidence for
a phenotype. J Gerontol A Biol Sci Med Sci 2001;56(3):M146–156.
7. Lang PO, Michel JP, Zekry D. Frailty syndrome: A transitional state in
a dynamic process. Gerontology 2009;55(5):539–49.
8. Wang CW, Lebsack A, Chau S, et al. The range and reproducibility of the
liver frailty index. Liver Transpl 2019;25:841–7.
9. Lai JC, Rahimi R, Verna EC, et al. Frailty associated withwaitlistmortality
independent of ascites and hepatic encephalopathy in a multi-center
study. Gastroenterology 2019;156:1675–82.
10. Yadav A, Chang YH, Carpenter S, et al. Relationship between
sarcopenia, six-minute walk distance and health-related quality of
life in liver transplant candidates. Clin Transplant 2015;29(2):
134–41.
11. Englesbe MJ, Patel SP, He K, et al. Sarcopenia and mortality after liver
transplantation. J Am Coll Surg 2010;211(2):271–8.
12. Riggio O, Andreoli A, Diana F, et al. Whole body and regional body
composition analysis by dual-energy X-ray absorptiometry in cirrhotic
patients. Eur J Clin Nutr 1997;51(12):810–4.
13. DiMartini A, Cruz RJ, Dew MA, et al. Muscle mass predicts outcomes
following liver transplantation. Liver Transpl 2013;19(11):1172–80.
14. TandonP,NeyM, Irwin I, et al. Severemuscle depletion in patients on the
liver transplant wait list: Its prevalence and independent prognostic value.
Liver Transpl 2012;18(10):1209–16.
15. Montano-Loza AJ. Severe muscle depletion predicts postoperative length
of stay but is not associated with survival after liver transplantation. Liver
Transpl 2014;20(11):1424.
16. Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, et al. Inclusion of
sarcopenia within MELD (MELD-Sarcopenia) and the prediction of
mortality in patients with cirrhosis. Clin Transl Gastroenterol 2015;6:
e102.
17. Kuo SZ, Ahmad M, Dunn MA, et al. Sarcopenia predicts posttransplant
mortality in acutely ill men undergoing urgent evaluation and liver
transplantation. Transplantation 2019;103(11):2312–7.
18. Sinclair M, Grossmann M, Hoermann R, et al. Testosterone therapy
increases muscle mass in men with cirrhosis and low testosterone: A
randomised controlled trial. J Hepatol 2016;65(5):906–13.
Open Access This is an open-access article distributed under the terms of the
Creative Commons Attribution-Non Commercial-No Derivatives License 4.0
(CCBY-NC-ND), where it is permissible to download and share the work pro-
vided it is properly cited. The work cannot be changed in any way or used
commercially without permission from the journal.
Study Highlights
WHAT IS KNOWN
3 Both frailty and sarcopenia are highly prevalent among
patients with cirrhosis.
3 Frailty and sarcopenia are predictors of mortality in this
population.
WHAT IS NEW HERE
3 Sarcopenia is associated with an over 2-fold increased
adjusted odds of frailty.
3 Less than half of the patients who met the criterion for frailty
also met the criterion for sarcopenia.
3 Sarcopenia is far less prevalent in frail women compared with
frail men.
TRANSLATIONAL IMPACT
3 There is a need for sex-specific therapeutic interventionwhen
targeting frailty among patients with cirrhosis.
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